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Objectives: ST-elevation and non-ST-elevation myocardial infarction (STEMI, NSTEMI) are considered two
distinct pathophysiologic entities. We evaluated cardiac troponin I (cTnI) release in STEMI and NSTEMI using a
“contemporary” (CV > 10 to 20% at the 99th percentile concentration) cTnI assay for patients undergoing
early percutaneous coronary intervention (PCI).
Design andmethods: 856 patients with suspected acute coronary syndrome consecutively admitted to the
Emergency Department of the Maggiore Hospital of Novara (225 STEMI and 135 NSTEMI) were selected
according to: 1) early (≤4 h from admission) and successful PCI; and 2) cTnI measurements at ED presentation
and within 24 h. The inﬂuence of the MI type on cTnI concentrations at baseline and after PCI as well as the
velocity of cTnI [cTnI V = absolute increase (after log conversion of cTnI measurements) / delay between the
two measurements] was studied by multiple regression analysis, adjusting for patient parameters.
Results: A statistically signiﬁcant interaction between MI type and time from symptoms was reported on
cTnI concentrations (p b 0.0001): STEMI and NSTEMI differed for cTnI releases at admission and after revascu-
larization. Higher cTnI V in STEMI was detectable in patients admitted within 6 h from symptoms. Baseline cTnI
concentrations were lower in patients with a history of coronary artery disease (CAD) and increased with aging
(p b 0.0001). In the elderly (>75 years), the cTnI V was signiﬁcantly increased.
Conclusion: STEMI and NSTEMI patients have different patterns and dynamics of cTnI release inﬂuenced by
the interaction with time from symptoms, by aging and history of CAD.© 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.Introduction
Several studies currently evaluate the prognostic performances of
cardiovascular biomarkers measured in the acute phase of a myocardial
infarction (MI) on case series including both patients with ST-elevation
myocardial infarction (STEMI) andMIwith non-ST-elevation at electro-
cardiogram (ECG) (NSTEMI) [1,2]. However the mixing of these two
populations of patients contrasts with the deﬁnition of acute MI stating
STEMI and NSTEMI as two distinct pathophysiologic entities accordingI, ST-elevation myocardial in-
ion at electrocardiogram myo-
aneous coronary intervention;
ment; CCU, Cardiac Care Unit;
tection; CVa, analytical coefﬁ-
elocity of cTnI release; CI, con-
Cliniche, Ospedale ‘Luigi Sacco’,
).
ociety of Clinical Chemists. Publishe
insights in the pathophysio
doi.org/10.1016/j.clinbiochemto the presence/absence of electrocardiographic ischemic changes [3].
ECG currently represents the sole clinical tool able to early catch the
main difference between pathological mechanisms underlying MI
types. In fact, although advancements have beenmade in imaging tech-
niques (i.e., cardiac magnetic resonance), these may still fail in the as-
sessment of heterogeneous and small infarct size in NSTEMI, resulting
below the threshold of detection [4].
Biomarkers can provide important information for both STEMI and
NSTEMI pathophysiologic mechanisms. Reports have suggested that
STEMI and NSTEMI have different patterns of release of inﬂammatory
and neurohormonal markers [5,6]. Inﬂammatory markers show a
remarkable prognostic value in NSTEMI whereas cardiac troponins
(cTns) are associated with better risk prediction for STEMI [7]. This
may reﬂect differences in the pattern of cTn release between STEMI
and NSTEMI and thus in the underlying biochemical and protein
expression proﬁles.
Current generation cTn assays [8,9] have led to an appreciation
that increased cTn concentrations can be associated with myocardial
necrosis independent from myocardial ischemia [10]. In particular,d by Elsevier Inc. All rights reserved.
logy of acute myocardial infarction detectable by a contemporary tro-
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assays (CV ≤ 10% at the 99th percentile) and “contemporary” assays
(CV > 10 to 20% at the 99th percentile)] [9] could contribute more
relevant information about the biochemical substrates underlying
STEMI and NSTEMI. Within this context, we sought to compare the
average patterns and the dynamics of cTnI release in STEMI and
NSTEMI patients undergoing early percutaneous coronary interven-
tion (PCI). The second aim was to investigate the effect of patient
characteristics on cTnI release occurring within the ﬁrst 24 h from
admission in each MI type.
Materials and methods
Patients
Eight hundred and ﬁfty-six patients with chest pain and suspected
acute coronary syndrome (ACS) were consecutively admitted to the
Emergency Department (ED) and then to the Cardiac Care Unit
(CCU) of the Maggiore Hospital of Novara from August 2006 (when
a cTnI new generation assay was introduced) to January 2009. From
this case series, 360 MI patients (225 STEMI and 135 NSTEMI) were
retrospectively selected according to the following criteria:
1) PCI performed early after admission (within 4 h) [11,12] according
to risk stratiﬁcation gauged on ECG ﬁndings and clinical evaluation
reported by running guidelines [12,13]. The resting 12-lead ECG
was obtained within 10 min after ﬁrst medical contact upon arrival
of the patient in the emergency room and immediately interpreted
by a qualiﬁed physician. The ﬁnding of persistent (>20 min)
ST-elevation suggested STEMI. In the absence of ST-elevation, addi-
tional recordings were obtained in symptomatic patients. NSTEMI
patients were preliminary selected according to ECG criteria and/
or creatine kinase MB (CK-MB) typical increase with at least one
value ≥ 99th percentile reference limit. High-risk NSTEMI patients
undergoing early reperfusion were identiﬁed according to the fol-
lowing criteria: a) ST-segment depression >0.5 mm (0.05 mV)
and b1.0 mm(0.1 mV) in two ormore contiguous leads, in a clinical
context of typical symptoms and coexisting cardiac disorders or
previous MI; b) ST-segment depression >1 mm (0.1 mV). Only a
small percentage of cases (~2%) were not classiﬁed accounting for
inconclusive data and were excluded from the case series;
2) successful PCI according to TIMI score;
3) availability of the ﬁrst cTnI measurement performed at ED presen-
tation and of a second measurement performed at CCU after PCI
within 24 h from admission;
4) detectable cTnI concentrations.
Exclusion criteria were successful thrombolysis, unsuccessful PCI
(TIMI from 0 to 2 at the end of the procedure) and emergency
surgery.
The time from symptoms and the time elapsed between the two
cTnI measurements were reported for all patients. In particular, the
time from symptom onset (namely duration of pre-hospital delay)
was deﬁned as the time interval between the onset of signs and
symptoms suggestive of MI and arrival in the ED (reported in h, as-
suming a tolerance of ±0.5 h). The delay time was obtained by the
cardiologist at patient's ED presentation during the clinical evaluation
and reported in the medical record together with other risk factors.
Hypertensionwas deﬁned as systolic tension higher than 140 mm Hg
and/or diastolic tension higher than 90 mm Hg or use of anti-
hypertensive drugs. Diabeteswas deﬁned as fasting venous plasma glu-
cose concentrations≥7.0 mmol/L or venous plasma glucose 2 h after in-
gestion of 75 g oral glucose load ≥11.1 mmol/L. Hypercholesterolemia
was deﬁned as fasting plasma cholesterol concentration ≥5.0 mmol/L.
A positive family history for coronary artery disease (CAD) was deﬁned
as presence of a CAD in a ﬁrst degree family member before the age of
55 years in males and 60 years in females. Chronic renal failure wasPlease cite this article as: Ferraro S, et al, New insights in the pathophysio
ponin assay, Clin Biochem (2013), http://dx.doi.org/10.1016/j.clinbiochemdeﬁned according to the presence of severely reduced kidney function
with an estimated glomerular ﬁltration rate≤29 mL/min/1.73 m. Coro-
nary and peripheral vasculopathy was deﬁned as wall narrowing
resulting in ischemia or non-inﬂammatory vascular lumen occlusion
resulting from thromboembolic disease.
The study was approved by the Institutional Review Board of the
Maggiore Hospital of Novara and informed consent was obtained
from all patients. Authors have complied with the World Medical
Association Declaration of Helsinki regarding ethical conduct of
research involving human subjects.
Sample processing and measurements
Venous blood samples were drawn via direct venipuncture into
tubes containing lithium heparin to obtain after centrifugation
(5 min, 1500 g at 4 °C) specimens of plasma for cTnI determination.
cTnI was determined by Advia Centaur TnI-Ultra™ assay [8] with an
analytical range of measurement of 6–50,000 ng/L, a limit of blank of
6 ng/L, and a 99th percentile value (cut-off) of 40 ng/L. From a
6-month retrospective evaluation of the two-level control materials
supplied by themanufacturer, the intra-laboratory analytical coefﬁcient
of variation (CVa) was 15% at 80 ng/L and 5% at 9000 ng/L.
Statistical analysis
The patient features were reported as dichotomous and continu-
ous variables. Accordingly, the statistically signiﬁcant differences
between these parameters in STEMI and NSTEMI were assessed by F
exact test and Mann–Whitney test. The results were adjusted by
adopting the Bonferroni correction for multiple comparisons.
The LOESS method (locally estimated scatterplot smoothing) was
used to visually assess the relationship between the two variables
(i.e., cTnI concentrations and time) in this large dataset where multi-
ple trends (i.e., thin lines from dataset points to arrows) can be hard
to visualize. LOESS is the most ﬂexible non-parametric regression
technique. This smoothing function, by making minimal assumptions
about the relationship among variables, can capture general patterns
while reducing the noise. The result of LOESS application is the solid
gray line through the moving central tendency of the relationship
between cTnI measurements and time. The smoothness parameter
(i.e., span) was set at 0.75: this means that each smoothed value
was determined through 75% of the neighboring points [14].
Descriptive analyses were employed to deﬁne the distributions of
cTnI concentrations in STEMI and NSTEMI patients. Because of the
skewed distributions, cTnI concentrations followed a logarithmic
transformation. The marker changes in STEMI and NSTEMI patients
were estimated as velocity of cTnI release (cTnI V) as follows:
log cTnI concentration after PCIð Þ− log cTnI concentration at admissionð Þ½ 
=time elapsed between the two measurements:
Multiple regression analysis was used to study the dependence
from MI type of:
1) cTnI concentrations detected at baseline;
2) cTnI concentrations detected after PCI;
3) cTnI V.
The analysis was adjusted for patient parameters as time from
symptom onset, age, gender, renal failure, and history of CAD. Age and
time from symptomswere included into themodels as continuous vari-
ables, accounting for possible non-linear effects by restricted cubic
splines [15]. In addition, the interaction between the time from symp-
toms andAMI typewas tested. The software used is the R-library Design
by Harrell (http://CRAN.R-project.org/package=rms).logy of acute myocardial infarction detectable by a contemporary tro-
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Dependence of cTnI concentrations from patient features
The baseline characteristics of the studied case series were
reported as dichotomous variables in Table 1A. Age, cTnI concentra-
tions at baseline and after PCI, cTnI absolute and percentage increase,
time elapsed between symptom onset to ED admission and time
between the two serial detections were reported as continuous vari-
ables in Table 1B. Because of the Bonferroni correction, the difference
was statistically signiﬁcant at the 0.05 level if the p-value was less
than 0.0036 (0.05/14). Thus, STEMI and NSTEMI results differed for
the proportion of patients with a previous history of CAD, age, time
elapsed from symptom onset, marker concentrations after PCI, and
absolute and relative increase. By comparing STEMI and NSTEMI,
it is relevant that there was no evidence of a difference in baseline
cTnI concentrations and in elapsed time between the two serial
measurements.
Because of the importance of pre-hospital delay onMI management
and patient outcomes [16,17], cTnI concentrations detected at ED ad-
mission and after PCI in each group of STEMI and NSTEMI patients
were reported ﬁrstly as a function of time from symptoms (Figs. 1A,
B) and then as a function of time from ED arrival (time = 0 for the
ﬁrst cTnI sample drawn at presentation Figs. 2A, B). In Figs. 1 and 2
solid gray lines indicated regression lines obtained by the locally
weighted method LOESS [14]. According to both ﬁgures, the shape of
the averaged trajectory derived from all STEMI and NSTEMI described
two different saturation curves: in STEMI a faster cTnI increase than
that in NSTEMI was observed.
The multivariate models investigating the effects of patient
features on baseline cTnI concentrations showed a statistically signif-
icant biological interaction between MI type and time from symptoms
(p b 0.0001, Fig. 3). In this context, a biological interaction is deﬁned
as the joint effect of two variables modulating cTnI release. From this
result, STEMI and NSTEMI differed for the cTnI release at admission
and before performing revascularization. In particular, by selecting 4
early and late time windows of clinical relevance, the ratio between
mean cTnI concentrations in STEMI and NSTEMI was found toTable 1
Patient characteristics reported as dichotomous (A) and continuous (B) data.
Variable
A
Gender: M, n (%)
Hypertension
Smokers
Diabetes
Vasculopathy
Renal failure
Family history of CAD
Hypercholesterolemia
Previous history of CAD
B
Age, median, 25th–75th percentiles (range) years
Time from symptoms to ED admission, median (25th–75th percentiles)
Time elapsed between cTnI measurement at ED admission and post-PCI cTnI measureme
(25th–75th percentiles)
cTnI concentrations at ED admission (ng/L), median (25th–75th percentiles)
cTnI concentrations after PCI (ng/L), median (25th–75th percentiles)
cTnI absolute increase between the two serial measurements (ng/L), median (25th–75th
% cTnI increase between the two serial measurements (with respect to ED measurement
(25th–75th percentiles)
Legend: NS = not signiﬁcant.
a Estimated as follows: absolute increase × 100 / concentration at ED in each STEMI/NS
increases.
Please cite this article as: Ferraro S, et al, New insights in the pathophysio
ponin assay, Clin Biochem (2013), http://dx.doi.org/10.1016/j.clinbiochemincrease with the increase of the time from symptoms. Thus, mean
cTnI concentrations in STEMI vs NSTEMI increased by:
1) 0.9-fold (95% CI: 0.5–1.5) at 3 h from symptoms to ED admission;
2) 1.4-fold (95% CI: 0.9–2.1) at 6 h;
3) 1.8-fold (95% CI: 1.2–2.8) at 8 h;
4) 3.3-fold (95% CI: 1.9–5.9) at 12 h.
Itwas notmarginal to highlight that the ratiowithin 5 hwas nearly 1.
In addition, cTnI baseline concentrations were inﬂuenced by the
presence of a previous history of CAD. In these patients, cTnI mean
concentrations were lower than those measured in patients without
a previous CAD (ratio between mean concentrations of 0.45, 95% CI:
0.28–0.74, p b 0.0001).
A slight increase of cTnI concentrations with age increase was
reported: patients 20 years older had cTnI 1.6-fold higher (95% CI:
1.2–2.2, p b 0.0001). No signiﬁcant relationships with marker con-
centrations were observed for gender and renal failure.
Concerning the ﬁrst cTnI concentration detected after PCI within
24 h from admission, STEMI and NSTEMI had a different pattern of
cTnI release. Also in this case the multivariate model showed a statis-
tically signiﬁcant biological interaction between MI type and time
from symptoms (p b 0.0001, Fig. 4). According to this result, STEMI
and NSTEMI had different amounts of cTnI release after revasculariza-
tion and the ratio of respective cTnI mean concentrations decreased
with the increase of the time from symptoms. In particular, by
selecting four time windows of clinical relevance after PCI, cTnI
concentrations in STEMI vs NSTEMI increased by:
1) 14.3-fold (95% CI: 6.0–34.1) at 6 h from symptoms;
2) 10.0-fold (95% CI: 5.5–18.2) at 12 h from symptoms;
3) 5.0-fold (95% CI: 3.2–7.7) at 24 h from symptoms;
4) 2.5-fold (95% CI: 0.9–6.3) at 36 h from symptoms.
In addition, patients with a past history of CAD had cTnI mean
concentrations 0.6-fold (95% CI: 0.4–0.9, p = 0.02) lower than
patients without. No signiﬁcant relationships with marker concentra-
tions were observed for age, gender and renal failure.STEMI
(n = 225)
NSTEMI
(n = 135)
p-Value
166 (73.8%) 87 (64.4%) NS
110 (48.9%) 80 (59.3%) NS
114 (50.7%) 51 (37.8%) NS
34 (15.1%) 30 (22.2%) NS
18 (8.0%) 13 (9.6%) NS
9 (4.0%) 5 (3.7%) NS
54 (24.0%) 30 (22.2%) NS
86 (38.2%) 50 (37.0%) NS
34 (15.1%) 39 (28.9%) 0.002
64, 53–74 (30–98) 69, 60–76 (39–94) 0.001
3.0 (2.0, 6.0) 8.0 (3.0, 12.0) b0.0001
nt, median 14.0 (9.0, 18.0) 11.5 (7.5, 17.0) NS
150 (50, 880) 200 (50, 910) NS
47.72 (14.78, 128.90) × 103 6.87 (1.99, 20.94) × 103 b0.0001
percentiles) 46.32 (12.00, 124.20) × 103 5.16 (1.13, 15.13) × 103 b0.0001
)a, median 19,640 (3281, 109900) 2012 (242, 9445) b0.0001
TEMI patient. Report of median and 25th–75th percentiles of the distribution of the %
logy of acute myocardial infarction detectable by a contemporary tro-
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Fig. 1. Patterns of cTnI release in STEMI (A) and NSTEMI (B) subsets derived according to admission and post-PCI concentrations as a function of time from symptoms. Tips indicate
the direction from the ﬁrst to the second measurement. The solid gray line is the interpolated shape of the patterns in STEMI/NSTEMI patients.
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In STEMI patients, cTnI V was signiﬁcantly higher (p b 0.0001)
than that of NSTEMI patients, deﬁned as (STEMI cTnI V) − (NSTEMI
cTnI V). According to the multivariable model, this difference was
found to be affected by the time elapsed from symptoms (Fig. 5A),
but in this case no biological interaction resulted as signiﬁcant. There-
fore by considering only patients admitted within 8 h (over this time
it was not statistically signiﬁcant) the difference ranged from 0.2 for
those admitted early (at 3 h from symptoms) to 0.1 for those admit-
ted later (at about 8 h). In particular, the difference was:
1) 0.2 (95% CI: 0.1–0.3) for patients admitted at 3 h from symptoms
to ED admission;
2) 0.1 (95% CI: 0.1–0.2) for patients admitted at 6 h;
3) 0.1 (95% CI: 0.0–0.2) for patients admitted at 8 h;
4) 0.0 (95% CI: 0.0–0.1) for patients admitted at 12 h.
In addition also the effect of age on cTnI V was statistically signif-
icant (p = 0.026) with a non-linear contribution (p = 0.01, Fig. 5B).
However, using 60 years as a threshold level for age, neither the dif-
ference between cTnI Vs at 40 and at 60 years (0.09, 95%CI: 0.0–0.2)
nor the difference between cTnI Vs at 75 and at 60 years (0.04,
95%CI: 0.0–0.1) was statistically signiﬁcant.Please cite this article as: Ferraro S, et al, New insights in the pathophysio
ponin assay, Clin Biochem (2013), http://dx.doi.org/10.1016/j.clinbiochemThe difference was statistically signiﬁcant only for patients older
than 75 years (>0.04) and tended to increase with increasing age
(Fig. 5B). The effect of CAD on cTnI V was not statistically signiﬁcant.
Discussion
There is a growing body of evidence that different pathophysiologic
mechanisms are involved in STEMI and NSTEMI. This is reinforced by
data on some cardiovascular biomarkers assuming distinct patterns of
release in each MI type [5–7]. It is also noteworthy that plaque disrup-
tion, thrombosis, coronary artery occlusion and myocardial necrosis
heavily differ greatly in persistence, degree and presence in STEMI
and NSTEMI [18]. Although suggestive preliminary data on the different
behaviors of inﬂammatory markers, necrosis markers and neurohor-
monal biomarkers are available, strong evidence about speciﬁc bio-
chemical substrates characterizing STEMI and NSTEMI is still lacking
[5–7,19].
Currently, because of the relevant improvement of analytical
sensitivity, cTns are the main candidate markers to introduce new
pathophysiologic insights in the heterogeneous framework of MI.
Assays with higher analytical sensitivity enable the measurement of
cTn concentrations that are undetectable with previous generation
assays. In particular “highly sensitive” assays, meeting guidelinelogy of acute myocardial infarction detectable by a contemporary tro-
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admission of STEMI and NSTEMI patients estimated from the regression model.
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Please cite this article as: Ferraro S, et al, New insights in the pathophysio
ponin assay, Clin Biochem (2013), http://dx.doi.org/10.1016/j.clinbiochemrequirements (i.e., CV ≤ 10% at the 99th percentile), allow the detec-
tion of >50%–95% of measurable normal values below the 99th per-
centile threshold, whereas a lower percentage (i.e., b50%) may be
detected by “contemporary assays” (i.e., CV > 10 to 20% at the 99th
percentile). Anyway, contemporary assays, deﬁned as “clinically
usable”, should gain the capability to measure cTn concentrations
allowing the characterization of myocardial necrosis early from the
onset of MI and even in the absence of overt ischemic disease [10].
In fact, the general improvement of analytical sensitivity has sparked
marked debate and discussion regarding the deﬁnition of MI and even
replacing the concept of traditional decision threshold with “decision
marker increase” for diagnosis [20]. In the present study, we have
exploited the increased sensitivity of a contemporary assay [8] to
compare the patterns of cTnI release between STEMI and NSTEMI pa-
tients that have undergone early reperfusion after admission in the
evolution of the acute event to catch differences in the biochemical
substrates. In addition, the possible modulatory effects of patient fea-
tures on cTnI releases have been investigated. The observed different
shapes of cTnI release curves between MI types suggested a more
rapid change in cTnI concentrations for STEMI with respect to
NSTEMI, in addition to the well known higher increase. In particular,
we have emphasized the relevance to report the effect of thelogy of acute myocardial infarction detectable by a contemporary tro-
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6 S. Ferraro et al. / Clinical Biochemistry xxx (2013) xxx–xxxtime from symptom onset (time from ED presentation added of
pre-hospital delay) on marker release. In fact, in these patients a
wide body of literature has shown that the length of pre-hospital
delay strongly affects morbidity and mortality rates and it is equally
associated with successful reperfusion [16,21,22]. In addition, interna-
tional guidelines recommend that reperfusion therapy should be
performed within 90 min after the onset of symptoms [23]. A recent
systematic review has shown the reliability of reporting pre-hospital
delay and the effect of patient features on it [24]. On the other hand,
studies comparing yearly trends of reported pre-hospital delay have
interestingly remarked that average delay times have remained essen-
tially unchanged during the past two decades [25].
We have evidenced by showing a biological interaction that the
time from symptom onset to ED admission differently modulated
the pattern of marker release in STEMI and NSTEMI. For instance,
cTnI concentrations at admission may appear quite similar in STEMI
and NSTEMI independent of the time from symptoms. Conversely,Time from symptom onset (h)m
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Please cite this article as: Ferraro S, et al, New insights in the pathophysio
ponin assay, Clin Biochem (2013), http://dx.doi.org/10.1016/j.clinbiochemthe biological interaction between time from symptoms and MI type
has revealed that cTnI concentrations on admission signiﬁcantly
rose in STEMI with respect to NSTEMI in those patients presenting
later at ED (after about 5 h from acute symptoms). This should reﬂect
a more rapid progression of necrosis in STEMI, supporting the idea
that an early revascularization in these patients is mandatory to
avoid the increasing loss of viable myocytes. Aside from the associa-
tion of longer ischemic times with more myocardial damage and
adverse clinical consequences, the effectiveness of reperfusion thera-
py has been shown to depend on time from symptom onset to ED
presentation, with the therapy having greatest beneﬁt for patients
who present with the shortest delay [17]. Indeed, by comparing the
trends of cTnI release after revascularization it is relevant to highlight
a pattern of rapid increase and subsequent fast decrease that occurs
only with STEMI. Conversely, the trend in NSTEMI mirrored an
ongoing slow marker increase at least up to 36 h from chest pain. In
particular, patients with early revascularization had higher cTnI
concentrations at 6 h from symptom onset when suffering for
STEMI than for NSTEMI. This difference tended to disappear with
longer delays from symptom onset and thus from revascularization.
The patterns of cTnI described in STEMI patients before and after
revascularization were rather expected in view of some old experi-
mental and clinical data aiming to elucidate the relationship between
the release of necrosis markers and the efﬁciency of reperfusion
[26–29]. One study by Remppis et al. [28] on patients with STEMI
(i.e., developing Q wave MI) reported a strict relationship between
successful reperfusion and highest and fast cTnT increase. In these
patients, cTnT concentrations peaked at nearly 14 h from symptom
onset and rapidly decreased, but being detectable up to the following
38 h. Similarly, other studies described a rapid rise and decrease of
CK-MB isoenzyme, myoglobin and cTn concentrations in a STEMI
model despite different times to peak and rates of protein clearance
from circulation. It was hypothesized that patients who underwent
early and successful reperfusion with such a pattern of release had a
sharp washout of necrosis markers [26–29]. In particular, a ratio
between cTnT concentrations detected at 14 h and at 38 h from
symptoms exceeding 1.09 appeared predictive for a successful
revascularization in patients who were treated early (b4 h from
symptoms). In contrast, borderline cTnT ratios corresponded to either
a poor or a late reperfusion or both [28].Age (y)
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may be associated with underperfused myocardium areas seemed
rather questionable [27]. It is likely that the prolonged ischemia
triggers tissue response that progressively reduces tissue perfusion
after revascularization [30]. For NSTEMI, a PCI performed later from
symptoms than in STEMI appeared to be the main cause of the slow
ongoing cTnI increase that persisted for several hours. In contrast to
the sharp washout of necrosis markers occurring in STEMI due to a
large vessel reopening within a short time period, a different washout
may characterize NSTEMI. In fact, in heterogeneous infarction the re-
perfusion of the microcirculation may be uneven and variable over
time [30]. This is likely to inﬂuence the pattern of release of necrosis
markers. In addition, we should take into account that cTnI release
after PCI may be further increased by the reperfusion injury, namely
irreversible damage to ischemic but viable tissue occurring with the
restoration of blood ﬂow after coronary occlusion [31]. Although it
is difﬁcult to distinguish the effect of washout and of reperfusion
damage on cTnI release, a recent study has reported that myocardial
salvage and reperfusion injury are more favorable in patients with
NSTEMI than in those with STEMI only when early invasive interven-
tion is undertaken [32]. This ﬁnding may further reinforce the
hypothesis that persistent high cTnI concentrations in NSTEMI are
likely due to late reperfusion with respect to the onset of chest pain.
The critical and complex inﬂuence of the time from symptoms on
cTnI release in bothMI types has suggested that a dynamic index such
as the cTnI V might gather more consistent information on the evolu-
tion of the myocardial injury compared to a simple measure of mark-
er increase after revascularization.
STEMI and NSTEMI patients tend to have quite similar cTnI V when
admitted late. Probably cTnI concentrations measured later from symp-
tomswhen necrosis is complete or just advanced are close to the satura-
tion point of the cTnI release curve. Thus in bothMI types no tendency to
a further increase seemed valuable. Under these conditions, thewashout
of cTn appeared to be associated with a slow release that theoretically
might be inﬂuenced by the activation of tissue response initiated by
prolonged ischemia for both STEMI and NSTEMI [30].
In comparing cTnI releases between MI types, we should take into
account the fact that results cannot be generalized to overall NSTEMI
patients, since we selected only those requiring urgent revasculariza-
tion and classiﬁed at a higher risk.
In addition to the time from symptoms, the critical effects exerted
by age and history of CAD in modulating the patterns of cTnI release
may signiﬁcantly contribute to marker concentrations and lead to
incorrect interpretation if not taken into consideration. As expected
[33,34], cTnI concentrations measured at admission for both STEMI
and NSTEMI patients tended to rise with increasing age. Interestingly,
the velocity of cTnI release signiﬁcantly increased in the elderly, but
only over the age of 75 years, possibly because of myocardial aging.
Patients with a history of ACS showed lower marker concentra-
tions both at admission and after PCI than patients with a ﬁrst acute
event, whereas no differences in the cTnI V emerged. The condition
of patients with a history of ACS could reﬂect the experimental
model of MI developing tolerance to prolonged ischemic insult,
namely ischemic preconditioning when the myocardium has been
previously exposed to brief periods of ischemia and reperfusion
[35]. Some experimental studies have investigated the effect of ische-
mic preconditioning on necrosis markers and the potential clinical
interpretation [36–38]. Basically, in MI patients undergoing myocar-
dial revascularization ischemic preconditioning was reported to
reduce periprocedural cTn concentrations and to delay myocardial
necrosis [36]. To date, our study is the ﬁrst to suggest that in vivo is-
chemic preconditioning might prevent exacerbation of myocardial
necrosis at the onset of a new acute event.
In conclusion, this study shows that patients with STEMI and
patients with NSTEMI classiﬁed at high risk have different patterns
and dynamics of cTnI release, which are further complicated by timePlease cite this article as: Ferraro S, et al, New insights in the pathophysio
ponin assay, Clin Biochem (2013), http://dx.doi.org/10.1016/j.clinbiochemfrom symptoms, aging andhistory of CAD. The different biochemical sub-
strates underlying STEMI and NSTEMI should discourage the investiga-
tion of cardiovascular markers in the wide framework of MI without
separating forMI type to avoid biased diagnostic/prognostic information.
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